Trial Condition(s):
Hepatocellular carcinoma
Hepatocellular carcinoma registry for Turkey (3K Trial)
Bayer Identifier:
15807
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Trial Purpose
This registry study is national, multi-center, prospective study without any interventions to the treatment strategies and/or decisions of the investigators. It is designed in order to determine the general profile of HCC patients in Turkey. Socio-demographic characteristics, family history, medical history and treatment pattern of HCC patients will be evaluated.
Inclusion Criteria
- To be diagnosed with hepatocellular carcinoma in last 3 months - To be older than 18 years old - To sign informed consent form (ICF)
Exclusion Criteria
- Patients that does not sign or withdraw informed consent form. - According to investigator’s opinion; existence of any situation/condition that will significantly complicate patient follow up. - Currently or previously taking part in 3K observational study
Trial Summary
Enrollment Goal
Trial Dates
Phase
Could I receive a placebo?
Products
Accepts Healthy Volunteers
Where to Participate
| Locations | |
|---|---|
Locations Investigative Site Many Locations, Turkey | Contact Us: E-mail: [email protected] Phone: (+) 1-888-8422937 |
Trial Design
Profile of the Hepatocellular Carcinoma patients in Turkey
Trial Type:
Observational
Intervention Type:
Other
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
1
Primary Outcome
- Descriptive analysis of HCC risk factorsi.e. smoking and alcohol consumption status; family history for hepatitis, HCC, and other malignancies; history of hepatic disease and blood transfusion; concomitant diseases; treatments appliedTimeframe: Baseline
- Descriptive analysis of clinical profile of newly diagnosed HCC patientsTimeframe: Baseline
Secondary Outcome
- Number of participants with underlying liver disease and family historyTimeframe: Baseline
- Treatment options as applied by doctors to HCC patientsTimeframe: Up to approximately 5 years
- Overall survival time since diagnosisTimeframe: Up to approximately 5 years
- Number of participants with adverse eventsTimeframe: Up to approximately 5 years
- Descriptive analysis of demographic characteristics of HCC patientsTimeframe: Baseline
- Descriptive analysis of clinical characteristics of HCC patientsTimeframe: Up to approximately 5 years
- Descriptive analysis of tumor propertiesTimeframe: Up to approximately 5 years
Additional Information
Copyright © Bayer
Powered by
